Indications
Crizotinib, also known as XALKORI, is indicated for the treatment of:
ALK‑positive or ROS1‑positive metastatic non‑small cell lung cancer (NSCLC)
ALK‑positive systemic anaplastic large cell lymphoma (ALCL)
ALK‑positive unresectable, recurrent or refractory inflammatory myofibroblastic tumors (IMT)
Purchase Channels for Crizotinib
Crizotinib is marketed in many countries including China and is covered by the national medical insurance catalogue. Major legitimate channels include:
Hospital Pharmacies
Advantages: Reliable drug source, direct medical guidance from physicians.
Disadvantages: Limited by hospital inventory; registration and consultation required.
Licensed Online Pharmacy Platforms
Advantages: Convenient and time‑saving, price comparison available.
Disadvantages: Must use certified platforms to avoid counterfeit drugs; valid prescription and pharmacist review required.
Side Effects of Crizotinib
Hepatotoxicity
May cause drug‑induced liver injury, which can be severe or fatal.
Requires regular liver function monitoring during treatment.
Manifestations: elevated ALT/AST, increased total bilirubin, fatigue, decreased appetite, jaundice.
Interstitial Lung Disease / Pneumonitis
May induce severe or life‑threatening interstitial lung disease or pneumonitis.
Clinical alerts: new or worsening dyspnea, cough (with or without sputum), fever.
Cardiac Side Effects
May affect cardiac electrophysiology and heart rate.
Includes QTc prolongation (risk of arrhythmia; requires ECG and electrolyte monitoring) and bradycardia (requires heart rate and blood pressure monitoring).
Visual Disorders
Common adverse reaction; may lead to vision loss in severe cases.
Manifestations: blurred vision, photopsia, floaters, photosensitivity, decreased visual acuity.
Note: The above list is not exhaustive. For additional adverse reactions, refer to the full prescribing information.
